This inventor holds 1 USPTO granted patent. Top assignee: Adaptimmune Limited. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Andrew Gerry: Innovator in T Cell Receptor Technology
Introduction
Andrew Gerry is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunology, particularly in the development of T cell receptors (TCRs). His work focuses on enhancing the specificity and efficacy of TCRs for therapeutic applications.
Latest Patents
Andrew Gerry holds a patent related to T cell receptors that bind the HLA-A*02 restricted peptide GLYDGMEHL, derived from the MAGE-A10 protein. This invention demonstrates excellent specificity profiles for the MAGE epitope. The patent also includes nucleic acids encoding the TCRs, engineered cells presenting the TCRs, and pharmaceutical compositions comprising these innovative components. He has 1 patent to his name.
Career Highlights
Andrew Gerry is associated with Adaptimmune Limited, a company that focuses on developing TCR therapies for cancer treatment. His work at Adaptimmune has positioned him as a key player in the advancement of personalized medicine.
Collaborations
Andrew collaborates with talented individuals such as Conor Hayes and Arsen Valeryevich Volkov. Their combined expertise contributes to the innovative research and development efforts at Adaptimmune.
Conclusion
Andrew Gerry's contributions to T cell receptor technology represent a significant advancement in cancer immunotherapy. His innovative work continues to pave the way for new therapeutic strategies in the fight against cancer.